Quantity of eligible people: CDEC talked about the uncertainty in the number of sufferers with moderately critical to intense hemophilia B in Canada eligible for etranacogene dezaparvovec. Medical specialists consulted by CADTH indicated that some individuals who will be classified as possessing moderate or moderate ailment can have a significant https://hemgenix05937.blogsvila.com/35969568/what-does-hemgenix-mean